Inhale Therapeutic Shares Are 'Undervalued,' Business Week Says
Bloomberg News
August 27, 1998, 11:55 p.m. ET
San Carlos California, Aug. 27 (Bloomberg) -- Inhale
Therapeutic Systems, whose shares fell 1 13/16 to 24 9/16 today,
is ''undervalued by the market,'' said Peter Ginsberg, an analyst
at Piper Jaffray Inc., in Business Week's ''Inside Wall Street''
column. Inhale, a biotechnology company that is working on
products that would allow diabetics and others to inhale their
medication, already has dry-powder formulations of medicines that
can be delivered to the bloodstream and lungs through a
proprietary inhaler, sales of which could top $10 billion,
Ginsberg said. Major investors in Inhale include Pfizer Inc.,
with a 5 percent stake, Eli Lilly & Co. and Baxter International
Inc., the magazine said.
Inhale shares are down 5.53 percent so far this year.
(BW, 9/7, 86, www.businessweek.com)
*--All magazine citations refer to Business Week
--Courtney Schlisserman in the New York newsroom (212) 318-2300
quote.bloomberg.com |
